<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01598701</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-12-0055</org_study_id>
    <nct_id>NCT01598701</nct_id>
  </id_info>
  <brief_title>Intravenous Acetaminophen in Craniotomy</brief_title>
  <official_title>The Opioid-Sparing and Analgesic Effects of IV Acetaminophen in Craniotomy: A Prospective, Randomized, Placebo-Controlled, Double-Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the use of intravenous Acetaminophen (OFIRMEV) as an
      effective adjunct therapeutic agent in patients undergoing craniotomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      General anesthesia will be induced by bolus administration of propofol (1.5-2.5 mg/kg IV),
      and fentanyl (2-3 µg/kg IV). Neuromuscular blockade will be achieved with bolus
      administration of rocuronium, vecuronium, or succinylcholine. Once the endotracheal tube is
      secured in place, the patient will be mechanically ventilated to an end-tidal CO2 of 35 mmHg.
      Additional procedures will include radial arterial line placement for invasive arterial blood
      pressure monitoring, as well as additional large-bore peripheral IV placements, or central
      line placement, if indicated. Anesthesia will be maintained with desflurane, propofol, and
      remifentanil.

      Once general anesthesia has been induced, but prior to the first surgical incision, the first
      dose of the interventional agent will be administered. Repeat doses will be administered
      every 6 hours until 24 hours from the time that the patient enters the PACU, for a total of
      up to 6 doses. Once the patient has been positioned and prepped for surgery, the surgeon will
      infiltrate the scalp with bupivacaine 0.5% with epinephrine 1:200,000 (15-20 ml) before skin
      incision.

      No other opioids or agents with analgesic properties (e.g., ketorolac, dexmedetomidine,
      ketamine) will be administered at any time during the operation. Additional medications that
      will be routinely administered for this procedure include dexamethasone 8-12mg IV prior to
      incision, and ondansetron 4mg IV at skin closure. Anticonvulsant drugs will be administered
      at the surgeon's request.

      Emergence and extubation will occur at the completion of the case per standard guidelines.
      The time of remifentanil infusion discontinuation and time of extubation will be noted. If
      necessary, extubation may occur in the post anesthesia recovery unit (PACU); otherwise,
      extubation will occur in the operating room.

      The patient will then be taken directly to the PACU. Inability to extubate a patient within
      two hours of completion of surgery will result in their withdrawal from the study. Once in
      the PACU, immediate postoperative vital signs will be recorded, including blood pressure,
      heart rate, respiratory rate, oxygen saturation, and RASS score.

      Pain scores will be assessed using the visual analog scale (VAS) upon entering the PACU or
      upon extubation in PACU (0 hours), and then again at 1, 2, 4, 8, 12, 16, 20, and 24 hours
      post-operatively. The VAS will be a 10 cm scale on a numerical scale of 0 (no pain) to 10
      (severe pain) that the patient will point to in order to indicate their current level of
      pain. Pain scores will be measured while the patient is at rest. Post-operative nausea will
      also be recorded on a 10 cm numeric rating scale (NRS) at the same time intervals, with 0
      indicating no nausea and 10 indicating severe nausea. All day-time VAS and NRS measurements
      will be made by a research assistant. Night-time measurements will be made by the nurse on
      the unit.

      While in the PACU, the time until the patient receives their first dose of analgesic medicine
      will be recorded. Patients will be given a 2mg nurse-administered dose of morphine upon
      request or if they report a pain score of ≥4/10, and will continue to be given morphine doses
      based on clinical assessment by the PACU/intensive care nurse, who will be blind to patient
      group allocation. The nurse will objectively assess the patient's pain score at least once an
      hour using the VAS pain scale, and an assessment of pain ≥4/10 will warrant an additional 2mg
      dose of morphine. Morphine dosage requirements will be recorded for 24 hours
      post-operatively. If morphine requirement is greater than 10mg in a 30 minute period or the
      patient develops an allergic reaction, pruritus, renal insufficiency, drowsiness,
      nausea/vomiting, or clinically relevant reason to change medication, the PACU supervising
      physician or ICU physician may use their clinical discretion to change the opioid rescue
      medication to hydromorphone (0.3mg doses). The reason for changing medication will be
      reported by the physician and recorded. The morphine equivalent of hydromorphone will be
      estimated to be 7 times the hydromorphone dose. The PACU/ICU nurses will also record any
      episodes of emesis, use of rescue anti-emetic medicine, and the occurrence of any other side
      effects.

      A post-operative neurologic examination will take place in the PACU. Criteria for a
      neurological exam to be complete is the patient's ability to successfully lift each leg off
      of the bed for more than two seconds on command, and to be able to hold up two fingers on
      each hand on command. If these criteria are not met prior to transferring the patient from
      the PACU to the ICU, a post-operative neurologic complication will be considered and the
      patient will be withdrawn from the study.

      The time until the patient is ready to be discharged from the PACU will also be noted.
      Patients with a modified Aldrete score of ≥ 8 (see Appendix 1) will be considered ready for
      discharge. These criteria will be assessed by either the research assistant or PACU staff.

      At the end of the 24 hour post-operative time period, a patient interview will be conducted.
      At this interview the patient will asked about their subjective satisfaction with their
      analgesic protocol, as well as any adverse effects they may have noticed. The 24 hour
      morphine consumption will also be recorded at this time.

      After the study is completed, patients may receive IV or oral acetaminophen therapy at the
      discretion of the primary physician.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2012</start_date>
  <completion_date type="Actual">March 30, 2016</completion_date>
  <primary_completion_date type="Actual">March 30, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-Operative Opioid Requirement</measure>
    <time_frame>24 hours post-operatively</time_frame>
    <description>Opioid Consumption will be monitored in the first 24 post-operative hours. All non-opioid analgesics are disallowed. Total opioid consumption was calculated based on morphine equivalents (MEs), where 1 mg of IV morphine was equivalent to 1 ME, and 1 mg IV hydromorphone was calculated as 7 MEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-Operative Pain</measure>
    <time_frame>24 Hours Post-Operatively</time_frame>
    <description>Patients will be assessed for pain using a Visual Analogue Scale (VAS) Scale at set time points after surgery (0,1,2,4,8,12,16,20,24 hours post-operatively). The Visual Analogue Scale (VAS) scale was measured on a scale of 0 - 10 (0 = no pain, 1-3 = mild, 4-6 = moderate, 7-10 = severe). Higher values on the VAS represent a worse outcome. The two rows below report: 1. the average VAS score for the least amount of pain reported per group and 2. the average VAS score of the worst amount of pain reported per group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Operative Side Effects</measure>
    <time_frame>24 Hours Post-Operatively</time_frame>
    <description>Patients will be monitored for 24 hours post-operatively to detect the incidence of any drug or opioid-related side effects. These side effects were not considered to be adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Extubation at Emergence From Anesthesia</measure>
    <time_frame>Time from of discontinuation of anesthetic to time of extubation, an average of 7 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for Patient to Meet Post-anesthesia Care Unit (PACU) Discharge Criteria</measure>
    <time_frame>From time of entry to PACU to time to meet PACU discharge criteria, an average of 12 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Intravenous Acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.</description>
    <arm_group_label>Intravenous Acetaminophen</arm_group_label>
    <other_name>OFIRMEV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100 mL 0.9% Sodium Chloride</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% Sodium Chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults

          -  Undergoing Craniotomy for Supratentorial Tumor Resection

          -  Weight between 50 and 120 kilograms

          -  ASA Physical Status I-III

          -  Be able to communicate verbally

          -  Be able to use Visual Analog Score

        Exclusion Criteria:

          -  Allergies to acetaminophen, morphine or any of the anesthetic agents required by the
             protocol.

          -  Use of opioids, tramadol, benzodiazepines, or gabapentin on a daily basis for &gt; 7 days
             prior to the day of surgery.

          -  Use of acetaminophen, NSAIDs, or any other analgesic medication in the 12 hours
             immediately prior to study enrollment.

          -  Hepatic insufficiency (elevated transaminases &gt; 1.5 times the upper limit of normal)
             or renal insufficiency (plasma creatinine &gt; 2mg/dl).

          -  Known or suspected history of alcohol or illicit drug abuse.

          -  Pregnant or breast-feeding.

          -  Surgical plan for infratentorial (suboccipital) craniotomy.

          -  Plan for neurophysiologic monitoring that precludes the use of neuromuscular blockade.

          -  Inability to communicate due to a language barrier, impaired consciousness, cognitive
             defect or intellectual disability.

          -  Uncontrolled Hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos A. Artime, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Sciences Center at Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sam D. Gumbert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Sciences Center at Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Hermann Hospital - Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Artime CA, Aijazi H, Zhang H, Syed T, Cai C, Gumbert SD, Ferrario L, Normand KC, Williams GW, Hagberg CA. Scheduled Intravenous Acetaminophen Improves Patient Satisfaction With Postcraniotomy Pain Management: A Prospective, Randomized, Placebo-controlled, Double-blind Study. J Neurosurg Anesthesiol. 2018 Jul;30(3):231-236. doi: 10.1097/ANA.0000000000000461.</citation>
    <PMID>29117012</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 9, 2012</study_first_submitted>
  <study_first_submitted_qc>May 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2012</study_first_posted>
  <results_first_submitted>February 28, 2017</results_first_submitted>
  <results_first_submitted_qc>May 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2018</results_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Carlos Artime</investigator_full_name>
    <investigator_title>Assistant Professor - Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Acetaminophen</keyword>
  <keyword>Intravenous Acetaminophen</keyword>
  <keyword>Opioid Requirement</keyword>
  <keyword>Pain</keyword>
  <keyword>Post-Operative Pain</keyword>
  <keyword>Craniotomy</keyword>
  <keyword>Post-Craniotomy Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intravenous Acetaminophen</title>
          <description>Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes.
Acetaminophen: Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen.
Placebo: 100 mL 0.9% Sodium Chloride</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intravenous Acetaminophen</title>
          <description>Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes.
Acetaminophen: Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen.
Placebo: 100 mL 0.9% Sodium Chloride</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.0" spread="16.3"/>
                    <measurement group_id="B2" value="51.5" spread="14.4"/>
                    <measurement group_id="B3" value="50.75" spread="15.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-Operative Opioid Requirement</title>
        <description>Opioid Consumption will be monitored in the first 24 post-operative hours. All non-opioid analgesics are disallowed. Total opioid consumption was calculated based on morphine equivalents (MEs), where 1 mg of IV morphine was equivalent to 1 ME, and 1 mg IV hydromorphone was calculated as 7 MEs.</description>
        <time_frame>24 hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Acetaminophen</title>
            <description>Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes.
Acetaminophen: Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen.
Placebo: 100 mL 0.9% Sodium Chloride</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Operative Opioid Requirement</title>
          <description>Opioid Consumption will be monitored in the first 24 post-operative hours. All non-opioid analgesics are disallowed. Total opioid consumption was calculated based on morphine equivalents (MEs), where 1 mg of IV morphine was equivalent to 1 ME, and 1 mg IV hydromorphone was calculated as 7 MEs.</description>
          <units>Morphine Equivalents</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="2" upper_limit="21"/>
                    <measurement group_id="O2" value="10.1" lower_limit="1" upper_limit="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Operative Pain</title>
        <description>Patients will be assessed for pain using a Visual Analogue Scale (VAS) Scale at set time points after surgery (0,1,2,4,8,12,16,20,24 hours post-operatively). The Visual Analogue Scale (VAS) scale was measured on a scale of 0 - 10 (0 = no pain, 1-3 = mild, 4-6 = moderate, 7-10 = severe). Higher values on the VAS represent a worse outcome. The two rows below report: 1. the average VAS score for the least amount of pain reported per group and 2. the average VAS score of the worst amount of pain reported per group.</description>
        <time_frame>24 Hours Post-Operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Acetaminophen</title>
            <description>Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes.
Acetaminophen: Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen.
Placebo: 100 mL 0.9% Sodium Chloride</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Operative Pain</title>
          <description>Patients will be assessed for pain using a Visual Analogue Scale (VAS) Scale at set time points after surgery (0,1,2,4,8,12,16,20,24 hours post-operatively). The Visual Analogue Scale (VAS) scale was measured on a scale of 0 - 10 (0 = no pain, 1-3 = mild, 4-6 = moderate, 7-10 = severe). Higher values on the VAS represent a worse outcome. The two rows below report: 1. the average VAS score for the least amount of pain reported per group and 2. the average VAS score of the worst amount of pain reported per group.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Least amount of pain reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.8"/>
                    <measurement group_id="O2" value="2.6" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worst amount of pain reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="2.5"/>
                    <measurement group_id="O2" value="6.4" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Operative Side Effects</title>
        <description>Patients will be monitored for 24 hours post-operatively to detect the incidence of any drug or opioid-related side effects. These side effects were not considered to be adverse events.</description>
        <time_frame>24 Hours Post-Operatively</time_frame>
        <population>The # analyzed does not match the # who completed or the overall # analyzed because data on all side effects was not collected for all participants who completed, either due to lack of collection of data by research/nursing staff (for emesis) or due to lack of reporting by participants on a questionnaire(for itching, dizziness, and drowsiness).</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Acetaminophen</title>
            <description>Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes.
Acetaminophen: Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen.
Placebo: 100 mL 0.9% Sodium Chloride</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Operative Side Effects</title>
          <description>Patients will be monitored for 24 hours post-operatively to detect the incidence of any drug or opioid-related side effects. These side effects were not considered to be adverse events.</description>
          <population>The # analyzed does not match the # who completed or the overall # analyzed because data on all side effects was not collected for all participants who completed, either due to lack of collection of data by research/nursing staff (for emesis) or due to lack of reporting by participants on a questionnaire(for itching, dizziness, and drowsiness).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Emesis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Extubation at Emergence From Anesthesia</title>
        <time_frame>Time from of discontinuation of anesthetic to time of extubation, an average of 7 minutes</time_frame>
        <population>The number analyzed is greater than the number completed because this data was collected for more patients than completed the study, and all data that was collected is reported here.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Acetaminophen</title>
            <description>Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes.
Acetaminophen: Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen.
Placebo: 100 mL 0.9% Sodium Chloride</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Extubation at Emergence From Anesthesia</title>
          <population>The number analyzed is greater than the number completed because this data was collected for more patients than completed the study, and all data that was collected is reported here.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="3" upper_limit="13"/>
                    <measurement group_id="O2" value="8" lower_limit="5" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time for Patient to Meet Post-anesthesia Care Unit (PACU) Discharge Criteria</title>
        <time_frame>From time of entry to PACU to time to meet PACU discharge criteria, an average of 12 minutes</time_frame>
        <population>The number analyzed is greater than the number completed because this data was collected for more patients than completed the study, and all data that was collected is reported here.</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Acetaminophen</title>
            <description>Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes.
Acetaminophen: Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen.
Placebo: 100 mL 0.9% Sodium Chloride</description>
          </group>
        </group_list>
        <measure>
          <title>Time for Patient to Meet Post-anesthesia Care Unit (PACU) Discharge Criteria</title>
          <population>The number analyzed is greater than the number completed because this data was collected for more patients than completed the study, and all data that was collected is reported here.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="7.2"/>
                    <measurement group_id="O2" value="13.5" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intravenous Acetaminophen</title>
          <description>Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes.
Acetaminophen: Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen.
Placebo: 100 mL 0.9% Sodium Chloride</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Not powered to detect differences in pain score. Patients were not given a patient-controlled analgesia device; rather, administration of morphine was dependent on nurse administration.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Carlos Artime, MD</name_or_title>
      <organization>University of Texas Health Science Center at Houston</organization>
      <phone>713-500-6200</phone>
      <email>Carlos.Artime@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

